ACOR
Acorda Therapeutics, Inc.
Set alert
52-week range unavailable
- Open
- 0.7838
- Prev close
- 0.661
- Mkt cap
- 821.03K
- Vol
- 321.67K
- Avg vol
- 0
- EPS
- 0.00
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 0.6116
- High
- 0.85
- Forward P/E
- -0.69
- Beta
- 1.46
- Short ratio
- 1.84
- Inst. own
- 13.22%
- Dividend
- 0.00
- Ex-div date
- Earnings
- May 9, 2024
- 50-d avg
- 9.33
- 200-d avg
- 12.55
- 1y target
- 0.00
Key statistics
- Market cap
- 821.03K
- Enterprise value
- 161.45M
- Trailing P/E
- 0.00
- Forward P/E
- -0.69
- PEG ratio
- 0.00
- Price / sales
- 0.01
- Price / book
- 0.00
- EPS (TTM)
- -203.57
- Beta
- 1.46
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- -214.95%
- Revenue (TTM)
- 117.63M
- Revenue growth
- 20.70%
- Free cash flow
- 20.14M
- Total cash
- 29.98M
- Total debt
- 190.90M
- Return on equity
- 0.00%
- Shares outstanding
- 1.24M
- Short % of float
- 0.66%
- 50-day average
- 9.33
- 200-day average
- 12.55
Analyst view
Consensus: buy
- Strong buy0
- Buy2
- Hold7
- Sell2
- Strong sell0
Next earnings
May 9, 2024
Expected May 9, 2024. Consensus EPS estimate 0.00.
Financials — quick view
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| May 9, 2024 | Mar 1, 2024 | 0.00 | — | — | — |
| Apr 1, 2024 | Dec 1, 2023 | 0.00 | — | — | — |
| Nov 13, 2023 | Sep 1, 2023 | 0.00 | — | — | — |
| Aug 8, 2023 | Jun 1, 2023 | 0.00 | — | — | — |
| May 11, 2023 | Mar 1, 2023 | 0.00 | — | — | — |
| Mar 9, 2023 | Dec 1, 2022 | 0.00 | — | — | — |
About Acorda Therapeutics, Inc.
Acorda Therapeutics, Inc., a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in adults with multiple sclerosis; and Inbrija, an inhaled levodopa for intermittent treatment of OFF periods in people with Parkinson's disease treated with a carbidopa/levodopa regimen. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, it has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra. The company was incorporated in 1995 and is headquartered in Pearl River, New York. On April 1, 2024, Acorda Therapeutics, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bankruptcy Court for the Southern District of New York.
- Sector
- Healthcare
- Industry
- Drug Manufacturers—Specialty & Generic
- Country
- United States
- Website
- acorda.com
News
- Acorda Therapeutics Announces Delisting from Nasdaq
- 12 Health Care Stocks Moving In Thursday's After-Market Session
- Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
- 12 Health Care Stocks Moving In Friday's Intraday Session
- Acorda Therapeutics Announces Nasdaq Delisting Notification
- Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
- Why Is Acorda Therapeutics (ACOR) Stock Down 72% Today?
- Acorda Therapeutics shares sink nearly 40% after bankruptcy filing
- Acorda Therapeutics and Merz Announce Signing of “Stalking Horse” Asset Purchase Agreement
- Acorda Therapeutics to Regain Global Commercialization Rights to FAMPYRA® by January 2025
Your note
Sign in to keep a note on ACOR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| BLANK BURKHARD | Officer | Stock Award(Grant) | Mar 2, 2021 | 18,527 |
| COHEN RON | Chief Executive Officer | Purchase | Mar 16, 2023 | 149,757 |
| GREENE BARRY E | Director | Conversion of Exercise of derivative security | May 20, 2018 | 1,273 |
| HINDMAN ANDREW ASA | Officer | Stock Award(Grant) | Mar 7, 2019 | 15,639 |
| LAWRENCE DAVID W | Officer | Stock Award(Grant) | Sep 16, 2020 | 15,976 |
| RANDALL LORIN J | Director | Sale | Nov 25, 2018 | 0 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Davidson Kempner Partners | 7.26% | 90,154 | 1.06M | Mar 30, 2023 |
| Davidson Kempner Capital Management LP | 4.44% | 55,145 | 717.44K | Jun 29, 2023 |
| Renaissance Technologies, LLC | 3.67% | 45,561 | 592.75K | Jun 29, 2023 |
| Acadian Asset Management. LLC | 2.75% | 34,131 | 444.04K | Jun 29, 2023 |
| Blackrock Inc. | 0.55% | 6,776 | 88.16K | Jun 29, 2023 |
| Telemetry Investments, L.L.C. | 0.53% | 6,625 | 101.59K | Dec 30, 2022 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Extended Market Index Fund | 0.64% | 7,989 | 103.94K | Jun 29, 2023 |
| Fidelity Extended Market Index Fund | 0.54% | 6,700 | 80.40K | May 30, 2023 |
| Bridgeway Funds Inc-Ultra Small Company Market Fund | 0.31% | 3,836 | 49.91K | Jun 29, 2023 |
| Fidelity Series Total Market Index Fund | 0.11% | 1,423 | 17.08K | May 30, 2023 |
| Fidelity Total Market Index Fund | 0.04% | 520 | 6.24K | May 30, 2023 |
| iShares Core S&P Total U.S. Stock Market ETF | 0.03% | 389 | 4.83K | Aug 30, 2023 |